Although traditional risk-factor screening approaches, such as uterine artery doppler, serum biomarkers (such as Vitamin D Levels, VEGF, PlGF, sFLT-1, and sFLT1/PlGF ratio, soluble endoglin (sEng), pregnancy-associated plasma protein A (PAPP-A) and alpha fetoprotein (AFP), T-Lymphocytes, have been proposed for the prediction of preeclampsia (Mikat et al., 2012), there is much need to identify novel promising biomarkers for an early diagnosis prior to symptoms appearance. This evidence concerns the gene ENG and preeclampsia.